NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it has entered into an exclusive license and development agreement with Vaccine Technologies, Inc. (VTI). Under the license agreement, Celldex has granted a worldwide fee- and royalty-bearing exclusive license to VTI to develop and commercialize Celldex’s CholeraGarde® and ETEC vaccine programs. Financial details of the agreement with VTI were not disclosed, but include upfront license fees, milestone payments and royalties on net sales of licensed products during the term of the agreement.
